
Shares of small-cap penny stock Addex Therapeutics Ltd. (NASDAQ:ADXN) are trading lower after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment. The company suspended its guidance amid the termination.
This has been attributed to consequences of COVID-19 related patient concerns about participation in clinical studies as well as staffing shortages and turnover within study sites.